Dose Escalation Study of No-Carrier-Added <sup>131</sup>I-Metaiodobenzylguanidine for Relapsed or Refractory Neuroblastoma: New Approaches to Neuroblastoma Therapy Consortium Trial - Concepedia

Concepedia

Publication | Open Access

Dose Escalation Study of No-Carrier-Added <sup>131</sup>I-Metaiodobenzylguanidine for Relapsed or Refractory Neuroblastoma: New Approaches to Neuroblastoma Therapy Consortium Trial

DOI Full Paper Access

63

Citations

23

References

2012

Year

Katherine K. Matthay, Brian Weiss, Judith G. Villablanca, John M. Maris, Gregory A. Yanik, Steven G. DuBois, James B. Stubbs, Susan Groshen, Denice Tsao‐Wei, Randall A. Hawkins,

Journal of Nuclear Medicine

Abstract

NCA (131)I-MIBG with autologous peripheral blood stem cell transplantation is feasible at 666 MBq/kg without significant nonhematologic toxicity and with promising activity.

References

	Year	Citations

Page 1